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Plasmablastic lymphoma (PBL) is an aggressive neoplasm exclusively occurring in AIDS patients. Recently, increasing
cases of human immunodeficiency virus (HIV)-negative PBL have been reported. No standard therapy protocol is
currently available since there is a great difference between PBL with and without HIV infection. Here, we present a
rather rare case of HIV-negative PBL in the neck that dramatically responded to radiotherapy alone. Our case highlights
the possibility of PBL in the neck and helps to expand our understanding of this separate lymphoma. The related literature
review summarized the clinicopathological features and treatment status of HIV-negative PBL.
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Plasmablastic lymphoma (PBL) is a rare entity which
mostly involves the oral cavity of human immunodefi-
ciency virus (HIV)-positive individuals. Recently, in-
creasing cases have been reported in HIV-negative
patients [1-5]. Extraoral sites, such as the central ner-
vous system, maxillary sinus, nasal cavity, gastrointes-
tinal tract, liver, and retroperitoneal region, can also be
involved [1-4,6-9]. Many differences on the aspect of
the clinicopathologic features and treatment response
between HIV-positive and -negative cases have been re-
vealed [10]. Here, we present a PBL case in an immuno-
competent woman for which radiotherapy alone provided
a remarkable response without severe side effects or inten-
sive chemotherapy.Case presentation
A 76-year-old female presented on October 22nd, 2013,
with a history of a painless lump in the left region of the
neck for about a month. She also complained of hoarse-
ness and drinking cough for one week. She did not suffer
from fever, night sweat, or significant weight loss. Her past
history was unremarkable except for hypertension for* Correspondence: lijie200461@126.com
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penicillin and cephalosporin. She denied any prior im-
munosuppressive conditions.
On physical examination, her blood pressure was 146/
70 mmHg. The trachea shifted to the right side. A 5 × 4 cm
firm mass was palpated in the lower left neck. No enlarged
lymph nodes were palpable in the bilateral axilla and groin.
Sternum tenderness was negative.
Laboratory investigations demonstrated a normal
complete blood cell count and a generally normal serum
biochemical profile. The levels of IgG, IgA, IgM, and lac-
tate dehydrogenase were normal. Erythrocyte sedimenta-
tion rate was elevated at 45 mm/h (normal, <20 mm/h).
β2-microglobulin was mildly elevated at 2.78 mg/L
(normal, <1.8 mg/L). Serum and urinary immunofixation
electrophoresis were both negative. The content of κ and
λ free light chain in the 24 h urine was normal. The level
of hepatitis B antigen was normal. Serum antibodies for
hepatitis C, HIV, and syphilis were negative.
Laryngoscopy showed left vocal cord paralysis. Ultra-
sound of the neck found a 50 mm × 44 mm heteroge-
neous hypoechoic mass in the left supraclavicular fossa
which had no clear delineation with the left lobe of the
thyroid. The patient then underwent a whole body PET/
CT scan which demonstrated a hypermetabolic mass in
the left supraclavicular fossa involving the left lobe of
the thyroid (Figure 1). There was no other abnormaltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Whole body PET/CT scan evaluated the involvement.
A hypermetabolic mass in the left supraclavicular fossa involved the
left lobe of the thyroid. The large primary tumor compressed
adjacent organs such as oropharynx, hypopharynx, larynx, trachea,
and esophagus. No other abnormal FDG uptake lesions were found.
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infiltration of medium to large atypical cells with round
nuclei and prominent nucleolus (Figure 2A). Neoplastic
cells strongly expressed Mum-1 (Figure 2B), CD 38
(Figure 2C), CD 138 (Figure 2D), and Ki-67 (80% expres-
sion, Figure 2E). The immunochemistry showed CK(–),
CD3(–), CD7(–), LCA(+), CD20(–), pax-5(–), CD30(–),
TdT(–), and CD34(–). In situ hybridization revealed
negativity for Epstein-Barr virus-encoded small RNA
(EBER) (Figure 2F). Bone marrow aspiration did not reveal
bone marrow involvement. Thus, the patient was diag-
nosed as PBL IA with an International Prognostic Index
score of 1.
Because of the patient’s age, intensive chemotherapy was
not performed. Instead, a vincristine and prednisone pre-
treatment regimen was given followed by 300 mg cyclo-
phosphamide and 10 mg dexamethasone intravenously.
The tumor had no response. However, the patient suffered
from fungal infection. Due to the severe side effect,
chemotherapy ceased and an effective antifungal treat-
ment was administered along with best supportive care. In
order to rapidly relieve the symptoms, she underwent
radiation to the primary tumor by intensity-modulatedradiotherapy (IMRT). After a dose of 28 Gy/14 f, the
tumor shrank significantly with a 71.4% response and all
the discomforts disappeared (Figure 3A,B). The radiother-
apy plan was then adjusted and the lymphatic drainage
area of the bilateral neck and the residual tumor were irra-
diated at a dose of 28 of Gy/14 f by the RapidArc® tech-
nique. After radiation with a dose of 56 Gy/28 f, the
tumor became smaller and the lesion exhibited an 87%
response (Figure 3C). To date, the patient is still alive.
Discussion
PBL was first described in the oral cavity of HIV-infected
individuals in 1997 by Delecluse et al. [11]. It was con-
sidered to have a strong correlation with HIV infection,
accounting for about 2.6% of AIDS-related lymphoma
[12]. HIV-positive PBL is highly aggressive with a poor
prognosis; its median survival after diagnosis is only
6 months [13,14]. Nowadays, increasing reports about
extraoral PBL of immunocompetent patients have
emerged. Research by Castillo et al. has shown that
HIV-negative PBL has different clinicopathological fea-
tures compared to HIV-positive PBL. HIV-positive PBL
patients are younger and more commonly exhibit oral
involvement and expression of CD20, CD56, and EBER.
HIV-positive PBL has a higher response to chemother-
apy and a relatively longer survival [10].
HIV-negative PBL is a distinct entity which requires
deep research. Because it is uncommon, we can only
analyze and summarize sporadic cases. Epstein-Barr virus
infection is more common in HIV-positive PBL [15].
Usually, PBL individuals without HIV infection have an
immunosuppression background. A report by Teruya-
Feldstein et al. demonstrated that, among six HIV negative
individuals, two cases had iatrogenic immunosuppression
[16]. One leg skin PBL patient had received a previous
renal transplant [17], and another suffering from ulcerative
colitis had been administered azathioprine [18]. In our
case, negativity for EBER and the lack of an immunosup-
pressive condition are rather rare.
Immunophenotypically, PBL strongly expresses CD38,
CD138, and MUM1, negatively expresses CD20 and PAX5,
and variably expresses CD79a, CD56, CD45, CD10, CD30,
and EBV-EBER [19]. In situ hybridization can detect the
expression of EBER in 74% of cases [20]. It is difficult to
differentiate PBL from plasmablastic plasma cell myeloma
especially in cases of extraoral sites without HIV infection.
In such circumstances, clinical presentation plays an
important role in differential diagnosis [13]. PBL has no
paraproteinemia, while the M-spike is essential for the
diagnosis of plasmablastic plasma cell myeloma. Bone
lytic lesions are rare in PBL except at the widely metastatic
stage. However, pain or fracture caused by osteolytic bone
destruction is the most common symptom for plasmablas-
tic plasma cell myeloma [13]. Usually, PBL has a higher
Figure 2 Histopathologic results of biopsy specimen of the left supraclavicular mass. (A) Hematoxylin-eosin stained section (×40) revealed
that diffuse infiltration of medium to large atypical cells with round nuclei and prominent nucleolus. (B–D) Immunochemistry examination for
Mum-1, CD 38, and CD 138 were intensively positive for neoplastic cells (×40). (E) Immunochemistry showed Ki-67 expressed in the nuclei of 80%
of neoplastic cells (×40). (F) In situ hybridization revealed negativity for Epstein-Barr virus-encoded small RNA (EBER) (×40).
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loma (5% to 60%) [13,21]. Our case has the classic immu-
nophenotypical and clinical features of PBL. Similar to the
case documented by Lin et al. [22], our case presented ini-
tially in a nodal site and had a dominant pattern of nodal
involvement in an immunocompetent individual. Due to
its rarity, there is no standard treatment for PBL. Current
treatment strategies of PBL often mirror those from
regimens for aggressive non-Hodgkin’s lymphoma [5,23].
Intensive chemotherapy followed by consolidate radio-
therapy can achieve an acceptable response for early stage
patients with good performance [6,15]. Saraceni et al.
reported that an HIV-negative, stage IIE PBL patient
attained complete remission of nearly 4 years after six
cycles of chemotherapy and irradiation of 45 Gy [6]. Simi-
larly, in a case of HIV-negative PBL in the anorectaljunction, three cycles of CHOP (cyclophosphamide, doxo-
rubicin, vincristine, and prednisone) chemotherapy and in-
volved field irradiation brought a complete remission of
nearly 5 years [15]. However, for elderly or poorly per-
forming individuals, radiotherapy is usually initiated to
rapidly relieve the discomfort. We must pay attention to
side effects carefully. Thakral et al. reported on an 84-
year-old female with PBL in the pelvis who suffered
from bowel ischemia and infarction in the radiation
field [13]. Advanced radiotherapy technologies, such as
IMRT and RapidArc®, can maximize the dose to the
tumor and minimize the dose to normal tissues. Thus,
radiation-related toxicity can be greatly reduced. In our
case, such advanced technologies were applied and the
patient responded dramatically to radiotherapy with
good tolerance.
Figure 3 Effect evaluation between pre-radiotherapy, radiotherapy
with a dose of 28 Gy/14 f, and after radiotherapy of 56 Gy/
28 f. (A) Before radiotherapy the giant primary tumor compressed the
trachea and esophagus and invaded the left lobe of the thyroid. (B) The
tumor shrank greatly after irradiation of 28 Gy/14 f. (C) After radiotherapy
of 56 Gy/28 f, the tumor was minimal residual and the response was
near complete remission.
Jiang et al. European Journal of Medical Research 2014, 19:64 Page 4 of 5
http://www.eurjmedres.com/content/19/1/64Recent studies have reported that bortezomib, a pro-
teasome inhibitor, could achieve good effects in HIV-
negative PBL, especially in recurrent or resistant cases
after several lines of treatment [5,23]. The primary
tumor was hypersensitive to bortezomib, which might
cause tumor lysis syndrome [23]. Thus, close surveillance
and best care support should be given after bortezomib.
Additionally, in HIV-positive PBL cases, bortezomib could
also achieve a dramatic response [24].
For HIV-negative PBL, autologous stem cell trans-
plantation could be of benefit for short-term disease-free
survival (up to 2 years) [25]. Other new drugs, such as
brentuximab vedotin, have been reported to achieve re-
sponse in CD30-positive cases [26]. Research data
showed that CD30 expression accounted for 30% of all
PBL cases [27-29]. Holderness et al. revealed that in aCD30-positive, left supraclavicular PBL mass without
HIV infection, brentuximab vedotin made the tumor
shrink remarkably while multiple chemotherapy and ir-
radiation had failed [26].
Conclusions
HIV-negative PBL is a rare but distinct clinicopathologi-
cal malignancy. There is no optimal treatment strategy.
Our case supplemented valuable information for HIV-
negative PBL in the neck. The effect of radiotherapy was
verified in this case. Thus, radiotherapy might be the
first option for elderly or poorly performing patients.
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